Separate terms with OR to return results that match either term.
 
Clear All

640 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Descending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9223 Lurbinectedin Zepzelca 0.1mg Chemotherapy Alkylating Agent Adduct Forming Agent No 2020 Jan. 1, 2021 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
NA Brigatinib Alunbrig 30 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2017 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
S0174 Dolasetron Mesylate Anzemet 50 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Jan. 1, 2002 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 April 1, 1998 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan. 1, 2000 In Use

Found 640 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.